PARTNERS

The Company welcomes new development partnerships and collaborations with both industry and academia for its proprietary oral T-cell activation therapy platform and product candidates. VAXIMM works with leading academic institutions and pharmaceutical companies in its development activities.

For more information, please contact us.
Please read the Terms of Use and Privacy Policy and confirm your acknowledgement by ticking the box:
Then you will be automatically forwarded to our e-mail form.

In November 2019, VAXIMM announced a strategic clinical trial collaboration and an equity investment agreement with NEC Corporation. Using NEC’s cutting-edge AI technology and VAXIMM’s novel oral T-cell immunotherapy technology, the two companies will co-develop personalized cancer vaccines, which will be evaluated in a Phase I clinical trial in various solid tumors. VAXIMM will be responsible for conducting the clinical trial, which is expected to be initiated in 2020. NEC has the option for development and commercialization rights to the program worldwide, except for China and other Asian territories outside of Japan.

In September 2018, VAXIMM announced the signing of a development and commercialization collaboration agreement with China Medical System Holdings Limited (CMS) (HKSE:0867). VAXIMM will collaborate with CMS, which will have the full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs, enabling the development and commercialization of VAXIMM’s pipeline of oral cancer immunotherapy candidates in the region. The parties will coordinate and share data from their respective clinical studies. VAXIMM will also receive development and commercial milestones and royalties based on the achievement of sales milestones by CMS. In parallel with the agreement, CMS has made an equity investment in VAXIMM, as part of VAXIMM’s current Series B financing.

In May 2017, VAXIMM announced a scientific collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. to evaluate avelumab, a human anti-PD-L1 antibody, in combination with VAXIMM’s VXM01. Under the terms of the agreement, VAXIMM is responsible for conducting two open-label Phase I/II trials with this combination – one in glioblastoma and one in metastatic colorectal cancer.